365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot ...
14 Elo 202527min
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and h...
7 Elo 202537min
363: What Vinay Prasad’s ouster means for biotech and the FDA
This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development came...
31 Heinä 202544min
362: A mother’s perspective on Sarepta’s gene therapy halt
We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and...
24 Heinä 202536min
361: Inside an FDA drug rejection, and layoffs at Sarepta
Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over manufacturing qualms? Ultragenyx CEO Emil Kakkis j...
17 Heinä 202543min
360: NIH grant cuts, FDA transparency questions and biotech M&A
On this week’s episode of the Readout LOUD: A closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FDA commissioner, and another big biotech acquisition...
10 Heinä 202525min
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
We invite STAT’s senior writer for infectious diseases, Helen Branswell, and Washington correspondent Chelsea Cirruzzo on to the podcast to discuss the latest news at the CDC. The agency is in the spo...
26 Kesä 202534min
358: FDA's gene therapy turmoil, and an alternative model for funding research
We discuss the tragic news that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics' gene therapy, raising renewed questions about the FDA's standards for appr...
19 Kesä 202530min
